hotspot -WSS

hotspot

author：knowledge 2025-10-01 17:19:17 - browse：4751

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

WSS

CDC recommends rationing of RSV shot due to shortages

The pink breast cancer awareness ribbon needs a redesign

Diversifying clinical trials isn't enough to close racial gaps: study

Cassava reveals details — and problems — with Alzheimer's study

White House pharmacy plagued with problems, investigation finds

Philips to halt sales of sleep apnea machines in U.S.

leisure time

hotspot

explore

Psychedelics group wrestles with new pharma identity

WHO may add ‘noma' to its list of neglected tropical diseases

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cassava reveals details — and problems — with Alzheimer's study

Drug repurposing or repositioning? The language matters

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Heart attack and stroke risk calculators need revising

Humana’s losses in Medicare Advantage tank its stock

Virginia high school admissions case could be legal follow

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

hotspot

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Zyn nicotine pouches become unlikely player in latest culture war

Telehealth options flood the market as retailers push virtual care

Biden's order seeks to regulate AI risk without stifling innovation

The FDA weighs the risks of candy

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

focus

hotspot

hotspot

entertainment